Contemporary problems in medicine – technique or ethics?

Main Article Content

Wojciech Płazak


Technical and pharmacological revolution in contemporary medicine has not resolved the ethical problems that seem to be more relevant today than ever before. Most of the papers that concern medical ethics focus on `great' problems, such as human genome sequencing, organizms cloning and quantitative or qualitative interference with life creation. This article, however, describes practical ethical problems that the doctors face in every-day practice. First of all, the problem of how thestandards of prophilaxis and treatment should be established when the costs exceed financial possibilities of a health system. Secondly, how to face the problem of rare diseases when the cost of a single patient treatment may be equal to the whole medical department budget. Thirdly, how to procede with elderly patients with multiple diseases qualified for invasive procedures. All of these examples share the common base: in these cases the technical equipment is at our disposal, yet we cannot or we do not want to use it.

Article Details

How to Cite
Płazak, W. (2018). Contemporary problems in medicine – technique or ethics?. Philosophical Problems in Science (Zagadnienia Filozoficzne W Nauce), (65), 177–193. Retrieved from
Proceedings of the PAU Commission on the Philosophy of Science


NICE Citizens Council Report. Ultra Orfan Drugs, 2004. [CorporatePage] NICE. Dostępne na: <> [dostęp 21.11.2018].

Tłustochowicz, W., 2011. Potrzebna terapia lekami biologicznymi [Rozmowa z prof. Witoldem Tłustochowiczem, konsultantem krajowym w dziedzinie reumatologii.]. [online] Dostępne na: <> [dostęp 21.11.2018].

Bonafede, M., Johnson, B.H., Princic, N., Shah, N. i Harrison, D.J., 2015. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics, 18(5), s. 376–389.

Yazdany, J., Dudley, R.A., Chen, R., Lin, G.A. i Tseng, C.-W., 2015. Coverage For High Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. Arthritis & rheumatology, [online] 67(6), s. 1474–1480. Dostępne na: <> [dostęp 21.11.2018].